Abstract

Introduction and objectivesEvaluation of differences in stroke prevention strategies in women in a prospective atrial fibrillation (AF) cohort. MethodsThe REFLEJA study included all outpatients with AF evaluated between October 2017 and October 2018 from a Spanish tertiary hospital center. The use and type of oral anticoagulation (OAC) and rhythm control strategies were analyzed. ResultsOf the 1499 patients included (age 73.8±11.1 years), 48.1% were women, having a higher CHA2DS2-VASc than men (2.90±1.62 vs 4.11±1.34; P<.001), and a similar use of antiarrhythmics (9.8 vs 12.2%; P=.15), although there was a lower indication for electrical cardioversion (8.6 vs 2.5%; P<.001) and catheter ablation (3.3 vs 1.5%; P=.036). The use of OAC was higher in women (91 vs 95.3%; P=.002) although less with direct anticoagulants (DOAC)(67.1 vs 60.1%; P=.012) and without differences in the use of reduced doses (13.2 vs 20%; P=.065). Previous stroke, previous electrical cardioversion, CHA2DS2-VASc ≥ 2, and de novo AF were predictors of greater use of DOAC, while chronic kidney disease, high bleeding risk (HAS-BLED ≥ 3), or moderate-severe non-rheumatic valvular heart disease were associated with a lower prescription. ConclusionsThe female population of the REFLEJA study presented a more unfavorable clinical profile than that of the men, with less rhythm control, although female sex was not independently associated with less use of OACs or NOAC.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call